AU2004281195A1 - Amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl derivatives, process and intermediate products for their preparation and medicaments containing these compounds - Google Patents

Description

DECLARATION 1, ALISON WINIFRED PENFOLD, B.A., Dip. (Translation), of Lloyd Wise, Commonwealth House, 1-19 New Oxford Street, London WC1A 1 LW, do hereby certify that I am conversant with the English and German languages and am a competent translator thereof and that to the best of my knowledge and belief the following is a true and correct translation made by me into the English language of the documents in respect of International Publication WO2005/037780 A2. Signed this 20th day of March 2006 Amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-y derivatives, process and intermediate products for their preparation and medicaments containing these compounds The present invention relates to novel amidomethyl-substituted 2-(4 sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-y derivatives with a potassium channel-blocking effect, in particular with an effect influencing the cardiovascular system, and also to medicaments containing these compounds. Furthermore, the invention relates to a process for the preparation of the novel compounds and intermediate products of this process. Indanes, benzopyrans and analogues of such compounds which have potassium channel-blocking effects, and in particular effects beneficially influencing the cardiovascular system, are already known from specification WO 00/12077 A (corresponds to US 6,150,356). Specification WO 00/58300 Al discloses chroman derivatives which are suitable as medicaments, in particular as antiarrhythmic medicaments. It was an object of the present invention to make available novel active substances for the treatment of in particular cardiovascular diseases, preferably cardiac arrhythmias, which are distinguished by high effectiveness with good compatibility and in the case of antiarrhythmic action also by a marked atrial-selective action profile. It has now surprisingly been found that a group according to the invention of novel amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-y derivatives possess potassium channel-blocking properties and are suitable for the treatment of cardiovascular diseases, preferably for the treatment of cardiac arrhythmias. The compounds according to the invention are distinguished by high effectiveness with good compatibility and in the case of anti-arrhythmic action also by a marked atrial selective action profile. In addition, the compounds according to the invention have properties which lead one to expect an additional effect influencing the immune system.

2 The subject of the invention is novel amidomethyl-substituted 2-(4 sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-y derivatives of the general formula 1, 0 0 RR4 R5 R N R3 II R6,N-" OH 0 03 R2I O R' wherein

R

1 is C 1

.

4 -alkyl,

R

2 is Cl4-alkyl,

R

3 is phenyl which is optionally substituted 1 to 2 times by halogen, CI4-alkyl, C 1 .4 alkoxy or trifluoromethyl; naphthyl or biphenyl,

R

4 is hydrogen; C 1

.

6 -alkyl or C 3

-

7 -cycloalkyl-C 1 .4-alkyl,

R

5 is hydrogen, and

R

6 is C 1

.

6 -alkyl; phenyl-C1.4-alkyl, the phenyl group of which is optionally substituted once by halogen; furyl-C 1 .4-alkyl or tetrahydronaphthyl, or

R

5 and R , together with the nitrogen to which they are bonded, form a piperazine ring which is optionally substituted by phenyl. Furthermore, a subject of the invention is medicaments containing the compounds of Formula 1. Furthermore, a subject of the invention is a process for the preparation of the compounds of Formula I and intermediate products of this process. Where in the compounds of Formula I or in other compounds described within the context of the present invention substituents are or contain C1.4-alkyl or C 1

.

6 -alkyl, these may each be straight-chain or branched. R' and R 2 preferably each have the meaning methyl.

R

3 preferably has the meaning phenyl which is optionally substituted 1 to 2 times by halogen, C1.4-alkyl, C 1 4-alkoxy or trifluoromethyl. In particular, R 3 has the meaning of phenyl substituted once by C 1 .4-alkyl. Where R 3 is halogen-substituted phenyl, fluorine, 3 chlorine, bromine and iodine are considered as halogen. As a particularly preferred meaning, R 3 stands for 4-ethylphenyl.

R

4 is preferably hydrogen, C 1

.

6 -alkyl or cyclopropyl-C 1 .4-alkyl, in particular cyclopropylmethyl. Where R 4 stands for C1.

6 -alkyl, this is in particular branched and preferably represents neopentyl, 2,2-dimethylbutyl, 2-ethylbutyl, 3-methylbutyl or 2-methylpropyl.

R

5 is preferably hydrogen.

R

6 preferably has the meanings phenyl-C 1 4 -alkyl, in particular benzyl or phenethyl, or the meaning tetrahydronaphthyl, in particular 1-tetrahydronaphthyl. (R)-1 tetrahydronaphthyl is preferred. Particularly preferred compounds of Formula I are selected from the group consisting of 2-(4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro 2H-chromen-6-yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide; 2-((3S,4R)-4-{[(4 ethylphenyl)sulphonyl]amino}-3-hyd roxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N [(1 R)-1,2,3,4-tetrahydronaphthalen-1 -yl]acetamide; N-benzyl-2-{4-[[(4 ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen 6-yl}acetamide; 2-{4-[[(4-ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl 3,4-dihydro-2H-chromen-6-yl}-N-(2-phenylethyl)acetamide and 2-(4-{[(4 methylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N 1,2,3,4-tetrahydronaphthalen-1-yl acetamide. According to the invention, the novel compounds of Formula I are obtained by reacting a compound of the general formula 11,

R

5 R4 OO O R2 wherein R 1 , R 2 , R 4 , R , and R 6 have the above meanings, with a compound of the general formula lil, X-SO2-R 3

III

4 wherein R 3 has the above meaning and X is a cleavable leaving group. The reaction can be carried out using a conventional wet-chemical process in an organic solvent which is inert under the reaction conditions, in particular a dipolar-aprotic solvent such as dichloromethane or in a mixture of such solvents and in the presence of a base. Suitable bases are non-nucleophilic organic nitrogen bases such as tertiary lower alkylamines, for example triethylamine. Liquid organic bases used in excess can also be used as solvents. If desired, the reaction can be catalysed by a known coupling aid such as 4-N,N dimethylaminopyridine (= DMAP). Suitable reaction temperatures are between room temperature and 80 0 C, for example 65 0 C. Suitable reaction pressures are between normal pressure and approximately 200 bar, for example 180 bar. If the compound of Formula IlIl which is used is liquid, it may be advantageous to remove the solvent used from the reaction mixture after the addition of the compound of Formula Ill to the compound of Formula 11 dissolved in the solvent in known manner, for example at reduced pressure. Where in the starting compounds of Formula il R 4 stands for hydrogen, it is expedient to use equimolar amounts of compound of Formula 111. Usually halogen, preferably chlorine or bromine, is used as leaving group X in compounds of Formula Ill. Furthermore, the reaction of a compound of Formula II with a compound of Formula Ill can also be performed in known manner on a solid phase, in particular on a reactive resin such as aminomethyl polystyrene (AMPS). This reaction variant can preferably be used for the preparation of smaller amounts of substance, for example on a scale of 1 to 10 mmol. Where synthesis is on a solid phase, preferably a readily filterable base such as known polymer-supported methylpiperidine (= PS methylpiperidine) can be used as base. Suitable reaction temperatures for solid-phase synthesis are between 10 C and 400C, preferably room temperature. Compounds of Formula I may be isolated in known manner from the reaction mixture and if necessary purified in known manner. Compounds of Formula 11 can be prepared by reacting an epoxide compound of the general formula IV, R5 N R1 4 R6 0O 3 R2 IV o I Io 0 R1 wherein R 1 , R 2 , R 5 and R 6 have the above meanings, in known manner with a nucleophilic organic nitrogen compound, preferably ammonia in aqueous solution, in a dipolar-protic 5 solvent such as a lower-alkyl alcohol, preferably ethanol. Suitable reaction temperatures are between room temperature and 60 0 C. Where compounds of Formula 11 are desired wherein R 4 stands for C 1 w-alkyl or C3.

7 -cycloalkyl-C 1

.

4 -alkyl, the resulting compound of Formula 11, wherein R 4 stands for hydrogen, can then be alkylated in known manner. The alkylation can be carried out in particular as an aminoalkylation, by first reacting the compound of Formula 11, wherein R 4 stands for hydrogen, with an aldehyde of the general formula V,

R

401 -CHO V wherein R 40 1 is hydrogen, C 2

.

5 -alkyl or C 3

-

7 -cycloalkyl-CO- 3 -alkyl, and then reducing the resulting imine intermediate product by addition of a reducing agent to the alkylamine compound of Formula 11. Suitable reducing agents are complex borohydrides such as NaBH 3 CN or known polymer-supported borohydride (= PS-BH 4 ). In a first variant, the reaction can be carried out in a polar-protic organic solvent which is inert under the reaction conditions, in particular methanol, the reduction of the imine being performed in situ without isolating it in the same solvent. Suitable reaction temperatures for this variant are between room temperature and 60 0 C, for example 50 0 C. In a second variant, the reaction of the compound of Formula 11, wherein R 4 stands for hydrogen, with an aldehyde of Formula V to form the imine intermediate product can be carried out in a dipolar-aprotic solvent, in particular tetrahydrofuran (= THF). In that case, it is advantageous to add catalytic amounts of a hydrophilic agent, for example an orthoester, in particular trimethyl orthoformate (= TMOF), to speed up the reaction. Then the imine intermediate product can be isolated and taken up in a polar-protic solvent stated above for the first variant, in order to perform the reduction in this solvent. This second variant may preferably be carried out at room temperature. In the nucleophilic ring-opening reaction of epoxides of Formula IV described above in two variants, as a rule compounds of Formula Il are obtained wherein the vicinal substituents in position 3 and in position 4 of the pyran ring, namely the hydroxyl group and the amino group, are each in the trans position to one another. Compounds of Formula il are novel compounds which are advantageously suitable as intermediate products for the preparation of novel pharmacologically active substances, for example for the preparation of the compounds of Formula 1. Compounds of Formula Ill and compounds of Formula V are known per se or can be prepared in known manner from known compounds.

6 Compounds of Formula IV can be prepared by reacting a compound of the general formula VI, R5 N R2 VI 0 R1 wherein R 1 , R 2 , R 5 and R 6 have the above meanings, in known manner with a peroxide compound capable of epoxide formation, preferably with m-chloroperbenzoic acid (MCPBA), in an organic polar-aprotic solvent which is inert under the reaction conditions, preferably dichloromethane, and in the presence of a base. A suitable base is in particular an aqueous solution of sodium hydrogen carbonate. The reaction may preferably be carried out at room temperature. Compounds of Formula I have at least in the vicinal carbon atoms in position 3 and in position 4 of the pyran ring in each case a chiral centre and can therefore occur in several isomeric forms. The subject of the invention is both the isomerically pure compounds of Formula I and mixtures of these isomers. The optically active compounds of Formula I can be obtained for example from the mixtures of the isomers of Formula I or from mixtures of the isomers of Formula 11 in known manner, e.g. by chromatographic separation on chiral separating materials. Mixtures of the isomers of Formula Il can also be obtained by reaction with suitable optically active acids, e.g. camphorsulphonic acid or D- or L-tartaric acid, and subsequent fractionation into the respective optical antipodes by fractional crystallisation of the salts obtained. The optically active compounds of Formula I can also be prepared directly by chiral synthesis. Where compounds of Formula I are to be prepared wherein the hydroxy substituent in position 3 of the pyran ring and the R 4

NSO

2

R

3 -substituent in position 4 of the pyran ring are in a stereochemically defined trans position to one another, in each case the starting point may be epoxides of Formula IV wherein the appropriate stereochemistry is already predetermined. Epoxides of Formula IV with correspondingly predetermined stereochemistry can for example be prepared by epoxidising alkenes of Formula VI in known manner with the aid of a chiral catalyst in accordance with the method of Jacobsen (cf. e.g. EP 0 521 099 Al). Where for example a compound of Formula I is to be prepared wherein the chiral centre in position 3 of the pyran ring is in 7 the S configuration and wherein the chiral centre in position 4 of the pyran ring is in the R configuration, an intermediate product of Formula VI can be reacted in the presence of a chiral catalyst, in particular (S,S)-manganese (Ill) salen and in the presence of an oxygen donor, in particular sodium hypochlorite in aqueous solution, in an organic solvent which is inert under the reaction conditions, in particular dichloromethane. Expediently, the reaction is carried out at a pH value between 9.5 and 11.5. To set a suitable pH value, preferably a buffer consisting of Na 2

HPO

4 and pyridine-N-oxide can be added to the reaction mixture. Suitable reaction temperatures are between -10*C and room temperature, preferably at 0*C. Where a compound of Formula I is to be prepared wherein the chiral centre in position 3 of the pyran ring is in the R configuration and wherein the chiral centre in position 4 of the pyran ring is in the S configuration, the procedure can be analogous to the directions described above, but (R,R)-manganese (111) salen is then used instead of (S,S)-manganese (Ill) salen. Compounds of Formula VI can be prepared by reacting a compound of the general formula VII, HO SR2 VII 0 0 R1 wherein R 1 and R 2 have the above meanings, with a compound of the general formula Vill,

HNR

5

R

6 VIII wherein R 5 and R 6 have the above meanings, in a manner known for aminoacylation. The carboxylic acids of Formula VII or their reactive derivatives such as acid halides, in particular acid chlorides or acid bromides, may be used as acylation agents. If the acids of Formula VII themselves are used as acylation agents, the reaction thereof with the amino compounds of Formula Vill can expediently also be carried out in the presence of a known coupling reagent, for example 1,1 -carbonyldiimidazole, ethyl chloroformate or an alkylcarbodiimide, e.g. N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide (= EDC), or a cycloalkylcarbodiimide such as dicyclohexylcarbodiimide. The acylation may take place in an organic solvent which is inert under the reaction conditions at temperatures from -30 0 C to +50 0 C, preferably at room temperature. Suitable solvents are halogenated 8 hydrocarbons such as dichloromethane or cyclic ethers such as tetrahydrofuran or dioxane or mixtures of these solvents. Compounds of Formula VII can be prepared by saponifying the ester group of a compound of the general formula IX, R7O R2 IX 0 R1 wherein R 1 and R 2 have the above meanings and R 7 is C 1 .4-alkyl, in known manner. The saponification can for example be carried out in a polar-protic solvent such as ethylene glycol by contacting with a base, for example a strong base such as dilute aqueous sodium hydroxide solution. Suitable reaction temperatures are between room temperature and the boiling point of the solvent or of the solvent mixture. Compounds of Formula IX can be prepared by reacting a compound of the general formula X,

R

7 0 0 Y-*"aOH wherein R 7 has the above meaning, with a compound of the general formula XI, R1 -0 >=/= XI R2 wherein R 1 and R 2 have the above meanings, in known manner. The reaction can be carried out in an organic solvent which is inert under the reaction conditions, such as toluene or xylene and in the presence of an acid with water being separated off by azeotropic distillation. A suitable acid is for example acetic acid or propionic acid. Advantageously, operation is with the addition of a catalyst such as a Lewis acid, for example phenylboronic acid. Suitable reaction temperatures are between room 9 temperature and the boiling point of the solvent or of the solvent mixture, for example around 120*C. The compounds of Formula X and Formula X are known per se or can be prepared in known manner from known compounds. The advantageous effects of compounds of Formula I as pharmacologically active active substances will become apparent from the following background: it is already known that substances which block endogenous cardiac potassium channels can be used as active substances to counter cardiovascular diseases, in particular to counter cardiac arrhythmias. By blocking outward-directed potassium currents in the heart, a prolongation of the action potential of the heart can be brought about which has a beneficial effect on arrhythmic heart conditions. Examples of this known treatment are Class Ill antiarrhythmic drugs. One problem of such non-specific potassium channel blockers is their low degree of selectivity with respect to their effect on different heart tissues. Thus for a relatively long time it has been assumed that in particular Class Ill antiarrhythmic drugs can lead to undesirable prolongation of the QT interval in the electrocardiogram (= ECG) and to polymorphic ventricular tachycardias ("torsades de pointes"), by means of which ultimately undesirable complications such as for example ventricular fibrillation can be triggered. For this reason, potassium channel blockers have been sought which are capable of selectively influencing the potassium currents of the atrium, but not of the ventricle. Since the Kv1.5-potassium channels in the heart which were discovered some time ago are located exclusively in the atrium, but not in the ventricle, it can be assumed that these K,1.5-potassium channel-blocking compounds are suitable as atrial-selective antiarrhythmic drugs. Kv1.5-potassium channels and other potassium channels are however located not only in the heart, but e.g. also in vessels of the body. Therefore it cannot always be ruled out that Kv1.5-potassium channel-blocking compounds may lead to increases in blood pressure owing to the blockade of potassium channels in the vessels. Kv1.5-potassium channel-blocking compounds which are free of side-effects which raise blood pressure are therefore preferred. Further undesirable side-effects which may occur on administration of many Kv1.5-potassium channel-blocking compounds are additional Class I-antiarrhythmic side-effects and also negatively inotropic effects. The compounds of Formula I are distinguished by an effect which particularly markedly and selectively blocks the cardiac Kv1.5-potassium channels. In addition to particularly good effectiveness and a marked atrial-selective antiarrhythmic action profile, the compounds of Formula I at most have slight undesirable side-effects such as increase 10 in blood pressure, Class l-antiarrhythmic side-effects and negatively inotropic effects. The compounds of Formula I are therefore indicated for the treatment and/or prophylaxis of cardiovascular diseases, in particular atrial fibrillation, atrial flutter and other cardiac arrhythmias, in larger mammals and humans. Furthermore, the compounds of Formula I exhibit a clear effect of blocking the K,1.3-potassium channels. K,1.3-potassium channels are preferentially located in cells of the immune system. A connection is made between blockade of the K,1.3-potassium channels and inter alia an anti-proliferative and/or immunosuppressive effect (cf. C. Beeton et al., The Journal of Immunology 166 (2001) 936-944). It can therefore be assumed of compounds which are capable of blocking K,1.3-potassium channels - for example the compounds of Formula I - that they are also suitable for the treatment and/or prophylaxis of proliferative, chronic inflammatory and autoimmune diseases such as multiple sclerosis. Description of the pharmacological test methods The example numbers quoted relate to the preparation examples described below. 1. In-vitro investigation of the K,1.5-potassium channel-blocking effect of the substances The Kv1.5-potassium channel-blocking effect of the substances is demonstrated in a known test model or analogously to this test model (cf. W. Hu et al., J. Pharmacol. Toxicol. Methods 34 (1995) 1-7). In this test model, a cell line of egg cells of the Chinese hamster (= "Chinese hamster oocytes", "CHO") is used which originates from a single cell and stably expresses the K,1.5-channel. By incubation overnight in a nutrient medium containing RbCI or in a "loading buffer" (all values in mM: RbCI 5, NaCl 140, CaC1 2 2, MgSO 4 1, HEPES buffer 10, glucose 5) the aforementioned oocytes are loaded with Rb* under the influence of the Na*/K* ATPase. Thereafter, a portion of the oocytes is incubated as a reference standard in the absence of an inhibitor, while another portion of the oocytes is incubated in the presence of the respective inhibitory test substance of Formula I. Then the oocytes are depolarised by increasing the extracellular potassium-ion concentration, which causes the K,1.5-potassium channels of the oocytes to open. In the absence of an inhibitor, the Rb* ions flow through the K,1.5-potassium channels into the liquid surrounding them. In the presence of an inhibitory test substance of Formula 1, on the other hand, the Rb" ions remain locked within the oocytes. The extent of the K,1.5 potassium channel-blocking effect of the test substances of Formula I is determined by 11 measuring the Rb* ion concentration in the liquid surrounding them by means of atomic absorption spectroscopy against a reference standard. Chinese hamster oocytes (see above) were cultivated in a known, RbCI-containing nutrient medium for CHO cells and placed in the sample wells of a 96-sample capacity sample plate ("96 well plate"). The oocytes were allowed to grow overnight in order to obtain monolayers of the oocytes. Then first of all the nutrient medium was pipetted off and each sample well was washed three times with 100 pl each time of a preincubation buffer of low potassium-ion concentration (all values in mM: KCl 5, NaCl 140, CaC1 2 2, MgSO 4 1, HEPES buffer 10, glucose 5). Then 50 pi of a solution of the respective test substance (stock solution in DMSO, dilution with preincubation buffer, final concentration in the test batch 10 pM) or of the solvent (as negative controls) was added to each sample well and incubated for 10 min. in each case at room temperature. Then 50 pl of a stimulation buffer with elevated potassium-ion concentration (KCI 145 mM, NaCl 0 mM, otherwise as preincubation buffer) was added to each sample well and the samples were then incubated for a further 10 min. at room temperature. In each case, 80 pi of the liquid surrounding the oocytes from each sample well was then transferred separately to the sample wells of an analysis sample plate, and the Rb* ion concentration in the liquids was determined by atomic absorption spectroscopy. The test substances were each double tested. The signal section which represented the K,1.5 component of the Rb* outflow was defined by using as positive control the known potassium channel blocker 4-AP in a high concentration (100 X IC50 for the K,1.5 channel). This made it possible to determine which portion of the Rb* outflow was dependent on the influence of the 4-AP and therefore is to be assigned to the K,1.5 channel. For the substances which in the concentration of 10 pM used led to a reduction in the Rb* outflow of at least 50%, additional tests were performed with lower concentrations of the test substance in order to be able to determine the half maximum effective concentration. In each case the concentration of half-maximum inhibition of the test substance of Formula I (IC5o) was given as characteristic variable. In this test model the test substances of Formula I listed in Table 1 below had the IC50 values given below: 12 Table 1: K,1.5-potassium channel-blocking effect of the test substances in vitro Example No. IC 50 2 2.0 4 1.6 6 5.0 7 1.5 8 0.5 9 2.9 10 1.6 11 3.2 12 3.2 13 6.5 15 4.0 16 6.3 17 2.65 18 2.7 19 2.5 20 2.9 21 3.3 22 3.4 23 4.3 24 5 25 5.2 26 5.2 27 5.6 2. In-vitro investigation of the K,1.3-potassium channel-blocking effect of the substances The K,1.3-potassium channel-blocking effect of the substances is demonstrated in a known test model (e.g. from Genion, Hamburg) or analogously to this test model (cf. J. Pl6sek and K. Sigler, J. Photochem. Photobiol. 33 (1996) 101-124). In this test model, known Chinese hamster oocytes (= CHO) are used which are stably transfected with the K,1.3-potassium channel. The blockade of the cell-inherent Kv1.3-potassium channel activity in the transfected cells is accompanied by a positive shift in the membrane potential from approx. -40 mV to -30 mV, whereas in the wild-type CHO cells investigated in parallel no significant shift in the membrane potential is triggered. A change in the membrane potential is thus connected to the reduction in the K,1.3-potassium channel activity. By blocking the K,1.3-potassium channels e.g. with substances of Formula I and 13 the resulting change in the membrane potential, an accumulation of a membrane potential-sensitive fluorescent dye in intracellular compartments of the oocytes and ultimately increasing fluorescence occurs. The change in the membrane potential of the oocytes is therefore measured indirectly via the increase in fluorescence of the membrane potential-sensitive dyes. The cells were transfected with the K,1.3 plasmid in known manner with a commercially obtainable transfection reagent (DMRIE-C from Gibco BRL, Germany). The successful transfection was verified by means of immunofluorescence and by "patch clamp" investigations of the potassium ion current. The fluorescence measurements were performed on a Tecan Safire fluorescence reader from Tecan, Germany. In each case, the increase in the fluorescent intensity caused by the blockade of the K,1.3-potassium channels in the oocytes with substances of Formula I in a concentration of 10 pM was determined as characteristic variable. The increase in the fluorescent intensity was given in each case in percent (%) compared with an increase in the fluorescent intensity caused by the reference substance margatoxin. Margatoxin is known as a selective K,1.3 potassium channel blocker (see e.g. M. Garcia-Calvo et al., J. Biol. Chem. 268 (1993) 18866-18874). In this test model the test substances of Formula I listed in Table 2 below had the percentages given below: 14 Table 2: Kv1.3-potassium channel-blocking effect of the test substances in vitro Example No. Increase In the fluorescent intensity (% margatoxin) 2 72 5 97 6 82 9 107 10 82 11 99 12 111 13 53 17 72 18 141 19 171 20 97 21 86 22 71 23 41 3. Investigation of the functional effectiveness of the substances on the atrium of rats' hearts in vitro The functional antiarrhythmic effectiveness of the substances is demonstrated in the test model set forth below. In this test model it is determined to what extent the Ky11.5 blocking substances of Formula I result in a prolongation of the functional refractory period in the left atrium of rats. The refractory period is the minimum possible elapsed time between the basic stimulus and additional stimulus in which a renewed contraction can be triggered. The extent of the prolongation of the functional refractory period is a measurement of the antiarrhythmic effectiveness of the substances according to the invention. The functional refractory period is determined by testing on the electrically stimulated preparation at what elapsed time from the preceding contraction a renewed contraction can be triggered by additional electrical stimuli. The hearts were removed from freshly sacrificed rats (Sprague-Dawley, Charles River, Germany). The left atria were isolated and fastened to force transducers in a temperature-controlled (30*C), gasified (02 95%, CO 2 5%) organ bath which was filled with modified Tyrode solution (all values in mM: NaCl 137; KCI 2.7; CaCl 2 1.8; MgCl 2 0.8; NaHCO 3 11.9; NaH 2

PO

4 0.6; glucose 5). In order to trigger regular contractions, the 15 preparations were electrically stimulated (rectangular pulses, pulse magnitude 3.5 x threshold stimulus, pulse width 1.5 ms, frequency 1 Hz). Initially, the initial value of the functional refractory period was determined by applying extra pulses in addition to the basic stimulus, the elapsed time from the preceding basic stimulus being shortened until no further additional contraction could be triggered. Then the cumulative addition of increasing concentrations (0.1 - 10 pM) of the substances of Formula I took place at intervals of 20 min. each, the refractory period being determined again in each case 18 min. after the addition had taken place. Before the measurement, stock solutions of the test substances (3.2 and 0.32 mM in 100% DMSO) were prepared. In order to achieve the desired final concentrations of the substances (0.1 - 10 pM) in the organ bath (volume 100 ml), corresponding volumes of these stock solutions were then poured into the organ bath. In each case the prolongation of the functional refractory period (FRP) in the left atrium of the rats' hearts in milliseconds observed after the addition of 10 pM of the respective substance of Formula I to the atrial preparations was given as characteristic variable. In this test model the test substances of Formula I listed in Table 3 below exhibited the prolongations of refractory period given below, higher values representing a greater antiarrhythmic effectiveness: 16 Table 3: FRP-prolonging effect of the test substances (10 pM) on the left atria of rats' hearts in vitro Example No. FRP prolongation [ms] 1 15 2 20 4 17 7 24 8 17 9 30 10 20 11 24 12 14 13 28 14 22 15 30 16 20 4. Investigation of the functional effectiveness of the substances on guinea-piq hearts in vivo In the test model shown below, it is shown that the substances according to the invention at most have slight undesirable proarrhythmic effects on repolarisation in the ventricle. For this, the influence of the compounds of Formula I on the effective refractory period (ERP) and other influencing variables on guinea-pig hearts were investigated in vivo. In this test model, non-selective potassium channel blockers not in accordance with the invention, which also block HERG and/or KVLQT1 channels, result in undesirable prolongation of the ERP and the QT time on an electrocardiogram (= ECG). The QT time is likewise a measurement of the repolarisation in the heart. Prolongations of the ERP and the QT time which are due to the substances are both each independently interpreted as indications of the risk of undesirable torsade-de-pointes arrhythmias occurring. Furthermore, also in each case the QRS interval was determined from the ECG as a measurement of the ventricular rate of spread of stimulus. Even a prolongation of the QRS interval caused by a test substance is connected with an increased risk of undesirable pro-arrhythmic side-effects. Therefore in this test model the lack of an ERP and QT time prolongation signifies a low risk, but the occurrence of a relevant ERP and QT prolongation on the other hand signifies an elevated risk of undesirable pro-arrhythmic effects. Also the lack of a prolongation of the QRS interval which is due to the substances due to the substances of Formula I investigated designates a low risk of undesirable pro- 17 arrhythmic side-effects, since lack of QRS prolongation indicates an undisturbed spread of stimulus in the ventricle. Conversely, a QRS prolongation, which is typically triggered by Class I antiarrhythmic drugs, indicates slowing of the conduction rate and may promote the occurrence of ventricular tachycardias up to ventricular fibrillation. Male guinea pigs (Dunkin-Hartley from Charles River) were anaesthetised (ketamine 50 mgkg, xylazine 10 mg/kg) and each of them was provided with a venous access via one jugular vein for administration of compounds of Formula I or a vehicle. A bipolar stimulation catheter was fed into the right ventricle of the guinea pigs via the other jugular vein (stimulation frequency 5 Hz). The arterial blood pressure was measured by a catheter located in the carotid artery which was connected to a Statham pressure transducer. The ECG was recorded via needle electrodes. The measured data were digitised via an A/D converter, recorded on a computer with suitable software (Ponemah Physiology Platform from Gould, USA) and printed out in parallel on a multichannel printer. After an equilibration period of 45 min., increasing doses of the compounds of Formula I or of the vehicle were administered intravenously (= i.v.) to the guinea pigs at 12-minute intervals. Before the first administration and in each case one minute after administration of increasing doses (0.1 - max. 30 pmol/kg) of the substances of Formula I, the effective refractory period was measured. For this, after five normal stimuli in each case an additional pulse was applied and the elapsed time thereof from the preceding pulse was increased until a heart action was triggered. The observed time interval corresponds to the ERP of the ventricular myocardium. In order to detect possible effects of the test substances on the blood pressure, in the same test model after each administration of substance the systolic and diastolic blood pressure was determined and compared with the previous blood-pressure level. The parameters were recorded automatically 1 and 8 min. after each administration of substance. Table 4 furthermore shows the changes in systolic blood pressure due to the compounds of Formula I given below (minus effects due to the vehicle). None of the compounds listed resulted in a relevant increase in blood pressure. In this test model, the test substances of Formula I listed in Table 4 below exhibited the effects listed below. Only statistically significant effects were listed, with a t test with a significance limit of P<0.05 being used for the statistical testing. In Table 4 below, the indication "n.s." (= "not statistically significant") means that the substance of the corresponding example does not have a statistically significant influence on the measured variable listed.

18 Table 4: Effect of the test substances (1 min. after administration of 10 pmol/kg i.v.) on the ERP, QT and QRS intervals in the ventricle of guinea pigs and simultaneously measured changes in the systolic blood pressure in vivo (n.s. = not statistically significant, negative values indicate shortening or reduction) Ex. No. ERP QT QRS syst. blood (ms) (ms) (ms) pressure (mm Hg) 1 n.s. n.s. n.s. n.s. 2 n.s. n.s. n.s. n.s. 4 n.s. n.s. n.s. n.s. 7 -8.2 n.s. n.s. -15.3 8 n.s. n.s. n.s. -10.7 10 -8.0 n.s. n.s. -15.9 11 n.s. n.s. n.s. n.s. 12 n.s. n.s. n.s. n.s. 13 n.s. n.s. n.s. n.s. 16 -7.5 n.s. n.s. -8.6 5. Investigation of the functional effectiveness of the substances on the hearts of anaesthetised cats in vivo In the test model shown below, it is shown that the substances according to the invention have a marked atrial-selective effect on the heart. After administration of the substances according to the invention, a significant increase in the atrial fibrillation threshold - i.e. the current intensity at which atrial fibrillation occurs - is observed. At the same time, on the other hand, the ventricular fibrillation threshold is influenced only minimally. Living cats were anaesthetised with chloralose/urethane (50/300 mg/kg i.v.) and were ventilated with ambient air. Then, following thoracotomy, stimulating electrodes were attached to the right atrium and the ventricle. The atrial and ventricular fibrillation thresholds were determined in known manner by application of rectangular pulses of increasing current intensity until atrial or ventricular fibrillation occurred (for performance see in detail: Br. J. Pharmac. 17 (1961) 167; Hdb. exp. Pharmacol. XVI/3 (1975) 131; Pharmacol. Res. 25 Suppl. 2 (1992) 156). The test substances of Formula I were dissolved in propylene glycol (80%) and administered intravenously in increasing doses (5 - 30 pmol/kg). Atrial and ventricular fibrillation thresholds were then determined at 19 5-minute intervals in known manner after the addition of the respective dose. The increase in the respective fibrillation threshold due to the substances investigated was expressed in percent of the value before administration of substance, i.e. a doubling of the fibrillation threshold corresponds to an increase of 100%. In this test model, the test substances of Formula I listed in Table 5 below had the effects given below. Table 5: Increase in the atrial (AFT) and ventricular fibrillation threshold (VFT) in anaesthetised cats in vivo (dose 30 pmol/kg i.v.) Ex. No. AFT VFT Selectivity factor (%) (%) (AFT:VFT) 1 66 22 3 2 261 15 17 4 226 19 12 9 213 29 7 10 241 19 13 The particularly good compatibility of the compounds according to the invention can also be demonstrated in further pharmacological test models. Thus for example it can be demonstrated in an in vitro test on cardiac muscle preparations of guinea pigs that the compounds of Formula I at most have slight Class l-antiarrhythmic side-effects. Furthermore, it can be demonstrated in an in vitro model on rats' hearts and in another in vitro model on guinea pigs' hearts that the compounds of Formula I at most cause slight negatively inotropic effects. The compounds of Formula I may be administered in conventional pharmaceutical preparations. In an individual case, special dosage forms may be indicated. The doses to be used may vary individually and will naturally vary according to the type of condition to be treated and the substance used. In general, however, medicinal forms with an active substance content of 0.2 to 500 mg, in particular 10 to 200 mg, active substance per individual dose are suitable for administration to humans and larger mammals. The compounds may be contained according to the invention, together with conventional pharmaceutical auxiliaries and/or excipients, in solid or liquid pharmaceutical preparations. Examples of solid preparations are preparations which can be administered orally, such as tablets, coated tablets, capsules, powders or granules, or alternatively suppositories. These preparations may contain conventional pharmaceutical inorganic 20 and/or organic excipients, such as talcum, lactose or starch, in addition to conventional pharmaceutical auxiliaries, for example lubricants or tablet disintegrating agents. Liquid preparations such as suspensions or emulsions of the active substances may contain the usual diluents such as water, oils and/or suspension agents such as polyethylene glycols and the like. Other auxiliaries may additionally be added, such as preservatives, taste correctives and the like. The active substances may be mixed and formulated with the pharmaceutical auxiliaries and/or excipients in known manner. For the preparation of solid medicament forms, the active substances may for example be mixed with the auxiliaries and/or excipients in conventional manner and may be wet or dry granulated. The granules or powder may be poured directly into capsules or be pressed into tablet cores in conventional manner. These may be coated in known manner if desired. The following examples are intended to explain the invention further, without limiting its scope. Example 1: 2-(4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6 yl)-N-1,2,3,4-tetrahydronaphthalen-1-y acetamide O

CH

3 HN 0 N OH 0 OO O c H3 A) 25 g methyl-4-hydroxyphenylacetate, 14.5 ml 3-methylbut-2-enal and 18.3 g phenylboronic acid were placed together under nitrogen atmosphere in 1 1 dry toluene and heated to boiling for 7 hours under reflux cooling. Then 60 ml glacial acetic acid was added to this receiving solution at room temperature (= RT) and the mixture was again heated to boiling for 7 hours under reflux cooling. It was allowed to cool to RT, the solvent was largely evaporated at reduced pressure and the remaining residue was poured into 300 ml of a 1:1 (v/v) mixture of ethyl acetate (= EA) and water. The pH value was adjusted to 5 by addition of solid sodium 21 bicarbonate, the organic phase was separated off and largely evaporated at reduced pressure. Chromatography of the remaining residue on silica gel (mobile phase: petroleum ether/EA 10:1 v/v) yielded 16 g methyl-(2,2-dimethyl-2H-chromen-6 yl)acetate as pale yellow oil, 1 H-NMR (400 MHz, CDCl 3 ) 5 [ppm]: 1.15 (s, 3 H) 1.27 (t, 3 H) 1.43 (s, 3 H) 1.60 - 1.85 (3 H) 1.97 (m, 1 H) 2.66 - 2.82 (4 H) 3.20 - 3.29 (3 H) 3.54 (dd, 1 H) 4.23 (dd, 1 H) 5.06 (m, 1 H) 5.28 (d, 1 H) 5.59 (d, 1 H) 6.55 (d, 1 H) 6.66 (d, 1 H) 6.97 (dd, 1 H) 7.03 - 7.18 (4 H) 7.35 (m, 2 H) 7.87 (m, 2 H); 1 3 C-NMR (101 MHz, CDCl 3 ) 5 [ppm]: 15.1 (q) 18.5 (q) 20.1 (t) 26.6 (q) 28.8 (t) 29.2 (t) 30.2 (t) 42.9 (t) 47.7 (d) 55.1 (d) 74.8 (d) 78.7 (s) 117.9 (d) 121.3 (s) 126.3 (d) 127.2 (s) 127.4 (d, 3 C) 128.2 (d) 128.8 (d) 128.9 (d, 2 C) 129.3 (d) 130.3 (d) 136.5 (s) 137.6 (s) 137.7 (s) 150.2 (s) 152.3 (s) 170.3 (s). B) 46 g of the methyl-(2,2-dimethyl-2H-chromen-6-yl)acetate obtained above (total amount from several analogous batches), 150 ml ethylene glycol and 400 ml of a 20%-strength aqueous sodium hydroxide solution were heated to boiling for 3 hours in 440 ml tetrahydrofuran (= THF) under reflux cooling. Then the resulting mixture was allowed to cool to RT, the solvent was largely evaporated at reduced pressure, and 200 ml tert. butylether and 300 ml water were added to the remaining residue. The mixture was stirred for 10 min. and then the aqueous phase was acidulated by addition of a 20%-strength aqueous hydrochloric acid solution to pH 6. The aqueous phase was extracted twice with 300 ml dichloromethane each time and the combined organic phases were dried over 20 g sodium sulphate. The solvent was largely evaporated at reduced pressure, petroleum ether was added to the remaining residue and a first resulting crystal fraction was filtered off from the solvent. The filtrate was concentrated again at reduced pressure, with another crystal fraction being produced. The combined crystal fractions were dried and 33.8 g 2,2-(dimethyl-2H-chromen-6-yl)acetic acid was obtained, which was used without further purification for the subsequent reaction, 1 H-NMR (400 MHz, CDCl 3 ) S [ppm]: 1.41 (s, 6 H) 3.52 (s, 2 H) 5.59 (d, 1 H) 6.27 (d, 1 H) 6.72 (d, 1 H) 6.88 (d, 1 H) 6.99 (dd, 1 H); 13 C-NMR (101 MHz, CDCl 3 ) 5 [ppm]: 28.1 (q, 2 C) 40.2 (t) 76.3 (s) 116.5 (d) 121.4 (s) 122.1 (d) 125.3 (s) 127.2 (d) 129.9 (d) 131.1 (d) 152.3 (s) 177.8 (s). C) 9.6 g 1,1-carbonyldiimidazole (= CDI) dissolved in 85 ml THF was slowly added to a solution of 11.7 g of the 2,2-dimethyl-2H-chromen-6-yl acetic acid obtained above in 100 ml THF and stirred for 30 min. at RT. 8.8 ml 1,2,3,4-tetrahydro-1-naphthylamine, dissolved in 30 ml THF, was dropped slowly into this receiving solution, the resulting 22 mixture was stirred for 1 h and left to stand overnight at RT. The solvent was largely evaporated at reduced pressure and the remaining residue was stirred with a mixture of diethyl ether and isopropanol (100:1 v/v) and crystallised. The resulting crystals were removed by suction and dried at 65 0 C and 20 bar. Chromatography of the diethyl ether / isopropanol washing liquid on silica gel yielded further intermediate product, which was combined with the main quantity and dried. 17.5 g 2-(2,2-dimethyl-2H-chromen-6-yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide was obtained as colourless solid, which was used without further purification for the subsequent reaction. 1 H-NMR (400 MHz, CDCl 3 ) 8 [ppm]: 1.41 (s, 6 H) 1.60 - 1.85 (3 H) 1.98 - 2.08 (1 H) 2.65 - 2.80 (2 H) 3.45 - 3.55 (2 H) 5.12 - 5.20 (1 H) 5.60 (d, 1 H) 5.66 (d, 1 H) 6.26 (d, 1 H) 6.71 (d, 1 H) 6.86 (d, 1 H) 6.96 (dd, 1 H) 7.02 - 7.07 (1 H) 7.08 - 7.17 (3 H); 13 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 20.2 (t) 28.0 (q, 2 C) 29.2 (t) 30.3 (t) 43.2 (t) 47.7 (d) 76.3 (s) 116.8 (d) 121.7 (s) 122.0 (d) 126.2 (d) 126.9 (s) 127.2 (d) 128.2 (d) 129.1 (d) 129.8 (d) 131.3 (d) 136.7 (s) 137.5 (s) 152.2 (s) 170.7 (s). D) 950 ml of a saturated aqueous sodium hydrogen carbonate solution was added to a solution of 11 g of the 2-(2,2-dimethyl-2H-chromen-6-yl)-N-1,2,3,4 tetrahydronaphthalen-1-yl acetamide obtained above in 600 ml dichloromethane. A total of 15 g m-chloroperoxybenzoic acid (= MCPBA) in three portions each of 5 g was added to this receiving solution at intervals of 5 min. each and the mixture was stirred for 18 hours at RT. The organic phase was separated off and very largely evaporated on a rotary evaporator at 650C and 20 bar. 2-(2,2-dimethyl-1a,7b dihydro-2H-oxireno[c]chromen-6-yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide was obtained as crude oil, which was used without further purification for the subsequent reaction, 'H-NMR (400 MHz, CDCl 3 ) 8 [ppm]: 1.23 (s, 6 H) 1.56 (s, 6 H) 1.63 - 1.85 (6 H) 1.97 - 2.10 (2 H) 2.65 - 2.82 (4 H) 3.43 - 3.56 (6 H) 3.84 - 3.89 (2 H) 5.12 - 5.22 (2 H) 5.62 -5-72 (2 H) 6.75 (d, 1 H) 6.76 (d, 1 H) 7.02 - 7.19 (10 H) 7.23 -7.27 (2 H); 1 3 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 20.1 (t) 22.6 (q) 25.7 (q) 29.2 (t) 30.2 (t) 43.1 (t) 47.7 (d) 50.8 (d) 62.7 (d) 73.2 (s) 118.6 (d) 120.5 (s) 126.2 (d) 126.3 (d) 127.2 (d) 127.3 (d) 127.5 (s) 128.2 (d) 128.3 (d) 129.2 (d) 130.5 (d) 131.1 (d) 131.2 (d) 136.5 (s) 137.5 (s) 137.6 (s) 151.8 (s) 170.4 (s). E) 88 ml of a 25%-strength aqueous ammonia solution was added to a solution of 16 g of the 2-(2,2-dimethyl-1a,7b-dihydro-2H-oxireno[c]chromen-6-y)-N-1,2,3,4 tetrahydronaphthalen-1-yl acetamide obtained above in 88 ml ethanol and the mixture was stirred for 18 hours at RT. Then 200 ml dichloromethane and 50 ml 23 methanol were added thereto and the mixture was stirred for a further 15 minutes. Then 200 ml water was added and the mixture was again stirred for 15 minutes. The organic phase was separated off and largely evaporated at reduced pressure. The remaining residue was stirred with 30 ml EA, filtered and dried on a rotary evaporator at 70*C and 20 bar. 3.1 g 2-(4-amino-3-hydroxy-2,2-dimethyl-3,4 dihydro-2H-chromen-6-y)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide was obtained as grey solid, which was used without further purification for the subsequent reaction. 1 H-NMR (400 MHz, DMSO-D 6 ) 8 [ppm]: 1.08 (s, 6 H) 1.35 (s, 6 H) 1.60 -1.95 (12 H) 2.63 -2.83 (4 H) 3.17 (d, 2 H) 3.32 - 3.40 (4 H) 3.49 (d, 2 H) 4.90 - 4.98 (2 H) 5.32 -5.38 (2 H) 6.62 (d, 2 H) 7.01 (dd, 2 H) 7.05 - 7.18 (8 H) 7.47 (d, 2 H) 8.32 -8.35 (2 H); 13 C-NMR (101 MHz, DMSO-D 6 ) 8 [ppm]: 18.6 (q) 19.9 (t) 27.0 (q) 28.7 (t) 29.8 (t) 41.7 (t) 46.2 (d) 50.8 (d) 76.6 (d) 77.8 (s) 115.6 (d) 125.5 (s) 125.6 (d) 125.7 (d) 126.5 (d) 127.9 (s) 128.0 (d) 128.1 (d) 128.3 (d) 128.4 (d) 128.6 (d) 136.9 (s) 137.5 (s) 150.5 (s) 169.8 (s). F) 1.67 g 4-ethyl benzenesulphonyl chloride was added dropwise to a solution of 3.75 g of the 2-(4-amino-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-y)-N-1,2,3,4 tetrahydronaphthalen-1-yl acetamide obtained above and 8.4 ml triethylamine in 160 ml dichloromethane. In addition 5 ml of dimethyl formamide (= DMF) was added and the resulting mixture was stirred for 18 hours at RT. Then 100 ml water was added and the mixture was stirred for another 5 minutes. The organic phase was separated off and the solvent was largely evaporated at reduced pressure. The remaining residue was chromatographed on silica gel (mobile phase: EA/cyclohexane/methanol 110:140:2 v/v/v) and the product phases were combined and reduced. The residue was stirred with petroleum ether/diethyl ether 10:1 v/v. The resulting crystals were removed by suction and dried on a rotary evaporator at 40*C and 25 bar. 2.3 g of the title compound was obtained as colourless crystals, 'H-NMR (400 MHz, CDCl 3 ) S [ppm] :m 1.14 (s, 3 H) 1.16 (s, 3 H) 1.26 (t, 3 H) 1.28 (t, 3 H) 1.44 (s, 6 H) 1.60 - 1.85 (8 H) 1.95 - 2.08 (2 H) 2.66 - 2.83 (8 H) 3.18 - 3.33 (6 H) 3.53 -3.63 (2 H) 4.18 - 4.28 (2 H) 5.02 -5.13 (2 H) 5.26 -5.37 (2 H) 5.52 -5.60 (2 H) 6.54 (d, 2 H) 6.66 - 6.71 (2 H) 6.95 - 7.19 (m, 10 H) 7.34 - 7.39 (4 H) 7.85 - 7.92 (4 H); 1 3 C-NMR (101 MHz, CDCl 3 ) 0 [ppm]: 15.1 (q) 18.4 (q) 20.1 (t) 26.6 (q) 28.8 (t) 29.2 (t) 30.2 (t) 42.9 (t) 47.7 (d) 47.8 (d) 55.1 (d) 74.9 (d) 75.0 (d) 78.6 (s) 78.7 (s) 118.0 (d) 121.0 (s) 126.2 (d) 126.3 (d) 127.2 (s) 127.4 (d) 128.2 (d) 128.8 (d) 128.9 (d) 129.2 (d) 129.3 (d) 130.3 (d) 136.5 (s) 137.6 (s) 150.3 (s) 152.3 (s) 170.3 (s).

24 Example 2: 2-((3S,4R)-4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H chromen-6-yl)-N-[(1 R)-1,2,3,4-tetrahydronaphthalen-1 -yl]acetamide O

CH

3 HN HOH A) 24.5 g CDI, 30 g 2,2-(dimethyl-2H-chromen-6-yl)acetic acid (for preparation see Example 1B)) and 22.8 ml (1R)-1,2,3,4-tetrahydro-1-naphthylamine were reacted according to the manner set forth above in Example 1C). 49 g 2-(2,2-dimethyl-2H chromen-6-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl acetamide was obtained as colourless crystals, which was used without further purification for the subsequent reaction. 1 H-NMR (400 MHz, CDCl 3 ) 5 [ppm]: 1.41 (s, 6 H) 1.60 - 1.85 (3 H) 1.98 2.08 (1 H) 2.65 - 2.80 (2 H) 3.45 - 3.55 (2 H) 5.12 - 5.20 (1 H) 5.60 (d, 1 H) 5.66 (d, 1 H) 6.26 (d, 1 H) 6.71 (d, 1 H) 6.86 (d, I H) 6.96 (dd, 1 H) 7.02 - 7.07 (1 H) 7.08 7.17 (3 H); 13 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 20.2 (t) 28.0 (q, 2 C) 29.2 (t) 30.3 (t) 43.2 (t) 47.7 (d) 76.3 (s) 116.8 (d) 121.7 (s) 122.0 (d) 126.2 (d) 126.9 (s) 127.2 (d) 128.2 (d) 129.1 (d) 129.8 (d) 131.3 (d) 136.7 (s) 137.5 (s) 152.2 (s) 170.7 (s). B) 5 g (S,S)-manganese-(ll)-salen and 7 g pyridine-N-oxide were added to a solution of 44 g of the 2-(2,2-dimethyl-2H-chromen-6-yl)-N-[(1R)-1,2,3,4 tetrahydronaphthalen-1-yl acetamide obtained above in 800 ml dichloromethane. The receiving solution thus obtained was cooled to 0*C and over 45 minutes a mixture of 660 ml of an aqueous sodium hypochlorite solution (Cl > 13%) and 88 ml of a 9%-strength aqueous solution of Na 2

HPO

4 was added. Stirring was continued for a further 3 hours at 0*C, then the organic phase was separated off and stirred for 1 hour with 500 g Celite@ 503. The solid was filtered off and subsequent washing was performed with dichloromethane until the filtrate was colourless. The filtrate was evaporated to dryness at reduced pressure. 40 g 2-[(1aS,7bS)-(2,2-dimethyl-1a,7b dihydro-2H-oxireno[c]chromen-6-yl]-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide was obtained as crude oil, which was used without further purification or characterisation for the subsequent reaction.

25 C) 40 g of the 2-[(1 aS,7bS)-(2,2-dimethyl-1 a,7b-dihydro-2H-oxireno[c]chromen-6-yl]-N 1,2,3,4-tetrahydronaphthalen-1-yl acetamide obtained above and 250 ml of a 25% strength aqueous ammonia solution were reacted corresponding to the manner given above in Example 1 E). Chromatography of the crude product on silica gel (mobile phase: dichloromethane / methanol / 25%-strength aqueous ammonia solution (75:50:2 v/v/v)) yielded 13.2 g 2-[(3S,4R)-4-amino-3-hydroxy-2,2-dimethyl 3,4-dihydro-2H-chromen-6-yl]-N-[(1 R)-1,2,3,4-tetrahydronaphthalen-1 -yl]acetamide as oil, which was used without further purification for the subsequent reaction, 1 H-NMR (400 MHz, DMSO 6 ) 8 [ppm]: 1.08 (s, 6 H) 1.35 (s, 6 H) 1.60 -1.95 (12 H) 2.63 -2.83 (4 H) 3.17 (d, 2 H) 3.32 - 3.40 (4 H) 3.49 (d, 2 H) 4.90 - 4.98 (2 H) 5.32 5.38 (2 H) 6.62 (d, 2 H) 7.01 (dd, 2 H) 7.05 - 7.18 (8 H) 7.47 (d, 2 H) 8.32 -8.35 (2 H); 13 C-NMR (101 MHz, DMSO-D 6 ) 8 [ppm]: 18.6 (q) 19.9 (t) 27.0 (q) 28.7 (t) 29.8 (t) 41.7 (t) 46.2 (d) 50.8 (d) 76.6 (d) 77.8 (s) 115.6 (d) 125.5 (s) 125.6 (d) 125.7 (d) 126.5 (d) 127.9 (s) 128.0 (d) 128.1 (d) 128.3 (d) 128.4 (d) 128.6 (d) 136.9 (s) 137.5 (s) 150.5 (s) 169.8 (s). D) 5.94 ml 4-ethyl benzenesulphonyl chloride, 13.2 g of the 2-[(3S,4R)-4-amino-3 hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl]-N-[(1 R)-1,2,3,4 tetrahydronaphthalen-1-yl]acetamide obtained above, 88 ml triethylamine and 4 ml dimethyl formamide were reacted corresponding to the manner given above in Example 1 F). 6.2 g of the title compound was obtained as solid, amorphous foam; 'H-NMR (400 MHz, CDCi 3 ) 8 [ppm]: 1.15 (s, 3 H) 1.26 (t, J=7.6 Hz, 3 H) 1.45 (s, 3 H) 1.60 - 1.85 (3 H) 2.01 (m, 1 H) 2.65 - 2.82 (4 H) 3.20 - 3.33 (3 H) 3.58 (dd, J=9.0, 3.0 Hz, 1 H) 4.23 (dd, J =9.0, 8.7 Hz, 1 H) 5.04 (m, 1 H) 5.16 (d, J=8.7 Hz, 1 H) 5.51 (d, J=8.5 Hz, 1 H) 6.54 (d, J=2.0 Hz, 1 H) 6.68 (d, J=8.4 Hz, 1 H) 6.98 (dd, J=8.4, 2.0 Hz, 1 H) 6.95 - 7.19 (4 H) 7.37 (m, 2 H) 7.87 (m, 2 H); 13 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 15.1 (q) 18.4 (q) 20.1 (t) 26.6 (q) 28.9 (t) 29.2 (t) 30.2 (t) 43.0 (t) 47.8 (d) 55.1 (d) 75.0 (d) 78.7 (s) 118.0 (d) 121.1 (s) 126.2 (d) 127.3 (s) 127.4 (d, 3 C) 128.2 (d) 128.7 (d) 129.0 (d, 2 C) 129.3 (d) 130.4 (d) 136.5 (s) 137.6 (s) 137.7 (s) 150.4 (s) 152.3 (s) 170.3 (s); [a]" = -8.3* (c=0.1, MeOH).

26 Example 3: N-benzyl-2-{4-[[(4-ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl-3,4 dihydro-2H-chromen-6-yl)acetamide I\ CH 3 NN HN \OH H 0 NOH 0 0 c H3 A) 16.2 g of CDI dissolved in 300 ml THF was slowly added to a solution of 19.7 g 2,2-dimethyl-2H-chromen-6-yl)acetic acid (for preparation see Example 1 B)) in 300 ml THF and stirred for 10 minutes at RT. 10.9 ml benzylamine was added slowly dropwise to this receiving solution and the resulting mixture was stirred for 1 hour. The solvent was largely evaporated at reduced pressure and the remaining residue was extracted once with 500 ml each of a mixture of EA and water (2:3 v/v). The organic phase was largely evaporated at reduced pressure and the remaining residue was chromatographed on silica gel (mobile phase: EA/cyclohexane 1:1 v/v). Drying of the product fractions on a rotary evaporator at 700C and 20 bar yielded 28 g N-benzyl-2-(2,2-dimethyl-2H-chromen-6-yl)acetamide as oil, which was used without further purification or characterisation for the subsequent reaction. B) 980 ml of a saturated aqueous sodium hydrogen carbonate solution was added to a solution of 28 g of the N-benzyl-2-(2,2-dimethyl-2H-chromen-6-yl)acetamide obtained above in 480 ml dichloromethane. A total of 44.1 g MCPBA in three portions each of 14.7 g was added to this receiving solution at intervals of 5 min. each and the mixture was stirred for 18 hours at RT. The organic phase was separated off, extracted once with 200 ml each time of a saturated aqueous sodium hydrogen carbonate solution and the organic phase was then very largely evaporated at reduced pressure. 35 g N-benzyl-2-(2,2-dimethyl-1a,7b-dihydro-2H oxireno[c]chromen-6-yl)acetamide was obtained as crude oil, which was used without further purification or characterisation for the subsequent reaction. C) 250 ml of a 25%-strength aqueous ammonia solution was added to a solution of 35 g of the N-benzyl-2-(2,2-dimethyl-1a,7b-dihydro-2H-oxireno[c]chromen-6- 27 yl)acetamide obtained above in 250 ml ethanol and the mixture was stirred for 18 hours at RT. The reaction mixture was poured into 500 ml water and extracted with 250 ml dichloromethane. The organic phase was separated off, dried over sodium sulphate and largely evaporated under reduced pressure. 200 ml diethyl ether was added to the remaining residue. The crystals produced after a while were removed by suction and dried on a rotary evaporator at 600C and 20 bar. 11 g 2-(4-amino-3 hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N-benzylacetamide was obtained as grey solid, which was used without further purification or characterisation for the subsequent reaction. D) 4 ml of trimethylacetaldehyde was added to a solution of 11 g of the 2-(4-amino-3 hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N-benzylacetamide obtained above in 200 ml methanol. 2.44 g of NaBH 3 CN was added in several portions and the resulting suspension was stirred for 2 hours at 500C. After cooling to RT, the reaction mixture was poured into 200 ml water. The aqueous phase was extracted once with 150 ml EA, the combined organic phases were dried over sodium sulphate and the solvent was largely evaporated at reduced pressure. Chromatography of the remaining residue on silica gel (mobile phase: EA/cyclohexane 1:1 v/v) and drying of the product fractions on a rotary evaporator yielded 10.8 g N-benzyl-2-[3-hydroxy 2,2-dimethyl-4-(neopentylamino)-3,4-dihydro-2H-chromen-6-yl]acetamide as colourless oil, 1 H-NMR (400 MHz, CDC13) 8 [ppm]: 1.15 (s, 3 H) 1.25 (t, 3 H) 1.43 (s, 3 H) 2.70 (q, 2 H) 3.18 - 3.31 (3 H) 3.55 (dd, 1 H) 4.22 (dd, 1 H) 4.30 (d, 2 H) 5.51 (d, 1 H) 5.81 (t, 1 H) 6.56 (d, 1 H) 6.67 (d, 1 H) 6.96 (dd, 1 H) 7.15 (m, 2 H) 7.21 7.30 (3 H) 7.32 (m, 2 H) 7.84 (m, 2 H); 13 C-NMR (101 MHz, CDC13) 8 [ppm]: 15.1 (q) 18.5 (q) 26.6 (q) 28.8 (t) 42.7 (t) 43.5 (t) 55.1 (d) 74.8 (d) 78.7 (s) 117.9 (d) 121.2 (s) 127.0 (s) 127.4 (d, 2 C) 127.5 (d, 3 C) 128.7 (d, 2 C) 128.9 (d, 3 C) 130.4 (d) 137.6 (s) 138.1 (s) 150.2 (s) 152.3 (s) 171.0 (s).

28 Example 4: N-benzyl-2-{4-[[(4-ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl-3,4 dihydro-2H-chromen-6-yl}acetamide

CH

3 N \ H 0 N OH 0 o c 3H 3 4.1 ml 4-ethyl benzenesulphonyl chloride was added dropwise to a solution of 10.8 g of the N-benzyl-2-[3-hydroxy-2,2-dimethyl-4-(neopentylamino)-3,4-dihydro-2H-chromen-6 yl]acetamide obtained above in Example 3 and 5 ml triethylamine in 100 ml dichloromethane. Dichloromethane was immediately very largely evaporated at reduced pressure and the resulting reaction mixture was stirred for 90 minutes at 65 0 C and 180 bar. The entire batch was poured into 150 ml water, and the aqueous phase was extracted once with 200 ml EA. The solvent was largely evaporated at reduced pressure, the remaining residue was dried over sodium sulphate and the remaining residue was chromatographed on silica gel (mobile phase: petroleum ether/EA 3:1 v/v). Drying the product fractions in an oil pump vacuum yielded 3.6 g of the title compound (2 conformers) as colourless oil, 1 H-NMR (400 MHz, CDCl 3 ) 8 [ppm]: 0.75 (s, 9H) 1.15 (s, 3 H) 1.26 (t, 3 H) 1.46 (s, 3 H) 2.36 (1 H) 2.65 - 2.75 (2 H) 2.90 -3.40 (4H) 3.86 (d,d 1 H) 4.39 (d, 2H) 4.76 (d, 1 H) 5.50 (t, 1 H) 6.48 (1 H) 6.73 (d, I H) 7.03 (dd, 1 H) 7.15 -7.35 (7 H) 7.81 (m, 2 H) major; 1 H-NMR (400 MHz, CDCI 3 ) 8 [ppm]: 0.86 (s, 9H) 1.19 (s, 3 H) 1.24 (t, 3 H) 1.51 (s, 3 H) 2.65 - 2.75 (2 H) 2.81 (d, 1 H) 3.25 -3.60 (4H) 4.25 - 4.61 (4 H) 4.60 (d,d 1H) 5.87 (t, 1 H) 6.73 (d, 1 H) 6.96 (dd, 1 H) 7.15 - 7.35 (8 H) 7.66 (m, 2 H) minor; 13 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 15.1 (q) 17.9 (q) 27.0 (q) 28.8 (q, 3C) 28.8 (t) 32.0 (s) 43.0 (t) 43.7 (t) 56.3 (t) 59.0 (d) 71.2 (d) 79.1 (s) 118.4 (d) 120.7 (s) 127.0 -130.4 (12C) 137.2 (s) 138.1 (s) 150.4 (s) 153.0 (s) 170.7 (s) major; 13 C-NMR (101 MHz, CDCl 3 ) 8 [ppm]: 15.1 (q) 18.6 (q) 27.2 (q) 28.0 (q, 3C) 28.8 (t) 33.5 (s) 43.3 (t) 43.6 (t) 63.0 (t) 63.4 (d) 73.2 (d) 78.8 (s) 118.0 (d) 122.0 (s) 125.7 - 129.8 (12C) 137.3 (s) 138.3 (s) 150.2 (s) 151.8 (s) 171.3 (s) minor.

29 Example 5: N-(4-chlorobenzyl)-2-(3-hydroxy-2,2-dimethyl-4-{[(3-methylphenyl)sulphonyl]amino}-3,4 dihydro-2H-chromen-6-yl)acetamide O Cl S CH 3 HN" \ H 0 N OH 0 0 CH H3 O ~ 3 A) 175.6 g methyl-4-hydroxyphenylacetate and 128.9 g phenylboronic acid were added to 3.5 I m-xylene. 88.9 g 3-methylbut-2-enal and 130 ml glacial acetic acid were added to this mixture. It was heated to 140*C in a Dean-Stark apparatus under nitrogen atmosphere until approximately 70% of the phenol had reacted (approximately 48 - 72 h). Then the reaction mixture was allowed to cool to RT, it was filtered and the solvent was evaporated at reduced pressure. The remaining residue was dissolved in a 1:1 mixture of THF and a 25%-strength aqueous ammonia solution (v/v) and stirred for 2 h. The THF was largely evaporated off at reduced pressure and EA was added. The organic phase was separated off, washed in succession with an aqueous 1 N NaOH and a saturated aqueous common salt solution and finally dried over sodium sulphate. The solvent was largely evaporated at reduced pressure and the remaining residue was chromatographed on silica gel (mobile phase: n-hexane/EA 15:1 to 10:1 v/v). Drying of the product fractions in an oil pump vacuum yielded 106 g methyl-(2,2-dimethyl-2H-chromen-6-yl)acetate as pale yellow oil, which was used without further characterisation for the subsequent reaction. B) 106 g of the methyl-(2,2-dimethyl-2H-chromen-6-yl)acetate obtained above was dissolved in 900 ml THF. A solution of 57.6 g LiOH in 900 ml water was added to this receiving solution and the mixture was stirred for 16 hours at RT. The THF was largely evaporated off at reduced pressure and the aqueous residue was acidulated by addition of an aqueous 6N hydrochloric acid solution. The aqueous phase was extracted with EA and the combined organic phases were washed in succession with a saturated aqueous common salt solution and with water. The organic phase was dried over sodium sulphate and the solvent was then very largely evaporated in 30 a vacuum. 97.6 g 2,2-(dimethyl-2H-chromen-6-yl)-acetic acid was obtained, which was used without further purification or characterisation for the subsequent reaction. C) 14.0 g of the 2,2-(dimethyl-2H-chromen-6-yl)acetic acid obtained above and 13.54 g EDCxHCI were dissolved in dichloromethane at RT. 10.Og 4-chlorobenzylamine was added dropwise to this receiving solution with stirring and the mixture was stirred for 16 hours at RT. Then the reaction mixture was washed in succession with water, 1 N aqueous hydrochloric acid solution and saturated aqueous common salt solution, and the organic phase was dried over sodium sulphate. Evaporation of the solvent at reduced pressure and drying of the remaining residue in an oil pump vacuum yielded 21.92 g of the crude N-4-chlorobenzyl-2-(2,2-dimethyl-2H-chromen-6-yl)acetamide, which was used without further purification or characterisation for the subsequent reaction. D) 700 ml of a saturated aqueous sodium hydrogen carbonate solution was added to a solution of 21.92 g of the N-4-chlorobenzyl-2-(2,2-dimethyl-2H-chromen-6 yl)acetamide obtained above in 600 ml dichloromethane. A total of 31.6 g MCPBA (72%) was added in portions to this receiving solution and stirred for 16 hours at RT. The organic phase was separated off, washed twice with a 5%-strength aqueous sodium hydrogen carbonate solution, dried over sodium sulphate and very largely evaporated at reduced pressure. Drying in an oil pump vacuum yielded N-(4 chlorobenzyl)-2-(2,2-dimethyl-1 a,7b-dihydro-2H-oxireno[c]chromen-6-yl)acetamide as crude oil, which was used without further purification or characterisation for the subsequent reaction. E) The N-(4-chlorobenzyl)-2-(2,2-dimethyl-1a,7b-dihydro-2H-oxireno[c]chromen-6 yl)acetamide obtained above was immediately poured into a mixture of so much ethanol and 25%-strength aqueous ammonia solution (6:5 v/v) that a 0.2 M solution of the compound was obtained, and it was stirred for 16 hours at 500C. Then it was allowed to cool to RT, and the solvent was largely evaporated at reduced pressure. The remaining residue was chromatographed on silica gel (mobile phase: gradient dichloromethane /methanol /25%-strength aqueous ammonia solution 97.5:2:0.5 to 90:9.5:0.5 v/v/v). Drying of the product fractions yielded 7.3 g 2-(4-amino-3-hydroxy 2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N-4-chlorobenzy acetamide, which was used without further purification for the subsequent reaction. The other regioisomer, 2-[3-amino-4-hydroxy-2,2-dimethylchromen-6-yl]-N-4-chlorobenzy acetamide, was not observed.

31 F) 15 mg PS-methylpiperidine and a solution of 6.0 mg 3-methylbenzenesulphonyl chloride in 0.5 ml dichloromethane were added in succession in a sample well of a sample plate for automatic parallel synthesis to a solution of 9 mg of the 2-(4-amino 3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N-4-chlorobenzy acetamide obtained above in 0.5 ml dichloromethane. It was shaken for 40 hours at RT and then 20 mg AMPS was added. It was shaken for a further 16 hours at RT before the liquid reaction phase was separated from the resin and the resin was washed twice with 1 ml dichloromethane each time. The solvent of the combined organic phases was evaporated off at reduced pressure and the title compound was obtained in a purity of 95% (determination by HPLC-MS), [M+H]* 529. Example 6: N-butyl-2-{4-[[(2,5-dimethoxyphenyl)sulphonyl](isobutyl)amino]-3-hydroxy-2,2-dimethyl 3,4-dihydro-2H-chromen-6-yl)acetamide OMe -S N \\ H 0 OMe - N OH OO 0 O ciS H 3 A) 10.0 g 2,2-(dimethyl-2H-chromen-6-yl)acetic acid (for preparation see Example 5B)), 9.67 g EDCxHCI and 5.41 g n-butylamine were reacted according to the manner set forth in Example 5C). 17.5 g crude N-(n-butyl)-2-(2,2-dimethyl-2H-chromen-6 yl)acetamide was obtained, which was used without further purification or characterisation for the subsequent reaction. B) 700 ml of a saturated aqueous sodium hydrogen carbonate solution was reacted with a solution of 17.5 g of the N-(n-butyl)-2-(2,2-dimethyl-2H-chromen-6 yl)acetamide obtained above in 600 ml dichloromethane and 31,6 g MCPBA (72%) corresponding to the manner set forth in Example 5D). The crude N-butyl-2-(2,2 dimethyl-1a,7b-dihydro-2H-oxireno[c]chromen-6-yl)acetamide was obtained, which 32 was used immediately without further purification or characterisation for the subsequent reaction. C) The n-butyl-2-(2,2-dimethyl-1a,7b-dihydro-2H-oxireno[c]chromen-6-yl)acetamide obtained above was immediately poured into a mixture of so much ethanol and 25% strength aqueous ammonia solution (6:5 v/v) that a 0.2 M solution of the compound was obtained and was treated further corresponding to the manner set forth in Example 5E). 7.4 g 2-(4-amino-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6 yl)-N-(n-butyl)acetamide was obtained, which was used without further purification for the subsequent reaction. The other regioisomer, 2-[3-amino-4-hydroxy-2,2 dimethylchromen-6-yl]-N-(n-butyl)acetamide, was not observed. D) 610 mg of the 2-(4-amino-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6-yl)-N (n-butyl)acetamide obtained above was dissolved in 20 ml THF and 220 pl TMOF was added. Then 197 mg ethyl butyraldehyde was added to this receiving solution and the reaction mixture was shaken for 16 hours at RT. The solvent was removed at reduced pressure, the remaining residue was taken up with 20 ml methanol, 7.9 g

PS-BH

4 was added and the reaction mixture was shaken for a further 16 hours at RT. The reaction mixture was then filtered and the reactive resin was washed with methanol. The combined filtrates were largely evaporated at reduced pressure, the remaining residue was dissolved in 20 ml dichloromethane and 0.4 equivalents of a known polymer-supported aldehyde (PS-CHO) and 0.6 equivalents of AMPS were added in succession. The mixture was shaken again for 16 hours at RT, the liquid phase was filtered off from the reactive resin and the latter was subsequently washed with THF. The combined liquid organic phases were evaporated at reduced pressure and 572 mg of 95% pure (determination by HPLC-MS) 2-[4-(2 ethylbutylamino)-3-hydroxy-2,2-dimethylchromen-6-yl]-N-(n-butyl)acetamide was obtained which was used without further purification or characterisation for the subsequent reaction. E) 20 mg PS-methylpiperidine resin and a solution of 37.1 mg 3,5-dimethoxy benzenesulphonyl chloride in 0.4 ml dichloromethane were added in succession in a sample well of a sample plate for automatic parallel synthesis to a solution of 14.8 mg of the 2-[4-(2-ethylbutylamino)-3-hydroxy-2,2-dimethylchromen-6-yl]-N-(n butyl)acetamide obtained above in 0.6 ml dichloromethane. The mixture was shaken for 168 hours at RT, the resin was filtered off and then 120 mg PS-AMPS was added to the filtrate. It was shaken for a further 16 hours at RT before the liquid reaction 33 phase was separated from the resin and the resin was washed twice with 1 ml dichloromethane each time. The solvent of the combined organic phases was evaporated off at reduced pressure and the title compound was obtained in a purity of 96% (determination by HPLC-MS), [M+H]* 591. The compounds of Formula I listed in Table 6 below can also be prepared according to the processes described in the examples above or according to processes analogous thereto: 34 Table 6: Further compounds of Formula 1: Ex. R' R 2 R3 R4 R 5 R6 *C- *C No. 3 4 7 Me Me 4-ethylphenyl neopentyl H benzyl S R 8 Me Me 4-ethylphenyl neopentyl H benzyl R S H (S)-tetrahydro- S R 9 Me Me 4-ethylphenyl H naphthalen-1-yl 10 Me Me 4-ethylphenyl neopentyl H phenylethyl trans 11 Me Me 4-ethylphenyl H H benzyl S R 12 Me Me 4-ethylphenyl H H phenylethyl trans H (S)-tetrahydro- trans 13 Me Me 3-fluorophenyl H naphthalen-1-yl H (S)-tetrahydro- trans 14 Me Me phenyl H naphthalen-1-yl H (S)-tetrahydro- trans 15 Me Me 4-methylphenyl H naphthalen-1-y 16 Me Me 4-ethylphenyl H -(CH 2

)

2

N-C

6

H

5 trans 17 Me Me 4-iodophenyl H n-butyl trans 18 Me Me 4-methylphenyl cyclopropylmethy H benzyl trans 19 Me Me 4-methylphenyl 3-methylbutyl H benzyl trans 2,5-dimethoxy- H trans 20 Me Me phenyl 2-ethylbutyl n-butyl 2,5-dimethoxy- H trans 21 Me Me phenyl 2-ethylbutyl 2-furylmethyl 3- H 1,2- trans 22 Me Me methoxyphenyl n-pentyl dimethylpropyl 4- H trans trifluoromethyl 23 Me Me phenyl 3-methylbutyl benzyl 3-chloro-4- H trans 24 Me Me fluorophenyl 2-methylpropyl n-propyl 25 Me Me 2-naphthyl 3-methylbutyl H benzyl trans 26 Me Me 4-biphenyl 3-methylbutyl H n-propyl trans 3- H trans 27 Me Me methoxyphenyl 3-methylbutyl I 4-chlorobenzyl trans = trans position of the substituents at C-3 and C-4, but mixture of the stereoisomers; Me = methyl; "S" and "R" each relate to the absolute configuration on the corresponding carbon.

35 Example I: Capsules containing 2 -(4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4 dihydro-2H-chromen-6-yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide: Capsules with the following composition per capsule were produced: 2-(4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2 dimethyl-3,4-dihydro-2H-chromen-6-yl)-N-1,2,3,4 tetrahydronaphthalen-1-yl acetamide 20 mg Corn starch 60 mg Lactose 300 mg EA q.s. The active substance, the corn starch and the lactose were processed into a homogeneous pasty mixture using EA. The paste was ground and the resulting granules were placed on a suitable tray and dried at 45 0 C in order to remove the solvent. The dried granules were passed through a crusher and mixed in a mixer with the further following auxiliaries: Talcum 5 mg Magnesium stearate 5 mg Corn starch 9 mg and then poured into 400 mg capsules (= capsule size 0).

Claims (9)

1. Compounds of the general formula I, R4 R 5 N R3 RS N 4OH 3 R2I 0 O R1 wherein R 1 is C14-alkyl, R 2 is C 1 . 4 -alkyl, R 3 is phenyl which is optionally substituted 1 to 2 times by halogen, C 1

4-alkyl, C 1 .4 alkoxy or trifluoromethyl; naphthyl or biphenyl, R 4 is hydrogen; C 1 .e-alkyl or C 3 . 7 -cycloalkyl-C 1 4-alkyl, R 5 is hydrogen, and R 6 is C 1 .-- alkyl; phenyl-C 1 . 4 -alkyl, the phenyl group of which is optionally substituted once by halogen; furyl-C 1 .4-alkyl or tetrahydronaphthyl, or R 5 and R , together with the nitrogen to which they are bonded, form a piperazine ring which is optionally substituted by phenyl. 2. Compounds according to Claim 1, wherein R 1 and R 2 are each methyl. 3. Compounds according to Claim 1, wherein R 3 is optionally once-substituted phenyl. 4. Compounds according to Claim 1, wherein R 4 is hydrogen, C 1 . 6 -alkyl or cyclopropyl-C1.4-alkyl.

5. Compounds according to Claim 1, wherein R6 is phenyl-C14-alkyl or tetrahydronaphthyl.

6. Compounds according to Claim 1, wherein in the pyran ring the carbon bearing the hydroxy substituent (C-3) is in the S configuration and the carbon bearing the nitrogen containing substituent (C-4) is in the R configuration. 37

7. Compounds of Formula I according to one of the preceding claims, which are selected from the group consisting of 2 -( 4 -{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen-6 yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide; 2-((3S,4R)-4-{[(4-ethylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H chromen-6-yl)-N-(1 R)-1,2,3,4-tetrahydronaphthalen-1 -yl]acetamide; N-benzyl-2-{4-[[(4-ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl-3,4 dihydro-2H-chromen-6-yl}acetamide; 2-{4-[[(4-ethylphenyl)sulphonyl](neopentyl)amino]-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H chromen-6-yl}-N-(2-phenylethyl)acetamide and 2-(4-{[(4-methylphenyl)sulphonyl]amino}-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-chromen 6-yl)-N-1,2,3,4-tetrahydronaphthalen-1-yl acetamide.

8. Medicament, containing a pharmacologically active quantity of a compound of Formula I according to Claim 1 and conventional pharmaceutical auxiliaries and/or excipients.

9. The use of compounds of Formula I according to Claim 1 for the preparation of medicaments for the treatment of cardiovascular diseases and/or for the treatment of proliferative, chronic inflammatory and autoimmune diseases.

10. A process for the preparation of compounds of Formula I, 0 0 R 5 R 4 N R3 R6,-N 4 OH Y 3 R2I 0 .R1 wherein R 1 is C 1 . 4 -alkyl, R 2 is C 1 .4-alkyl, 38 R 3 is phenyl which is optionally substituted 1 to 2 times by halogen, C1.4-alkyl, C 1 .4 alkoxy or trifluoromethyl; naphthyl or biphenyl, R 4 is hydrogen; C 1 .e-alkyl or Ca. 7 -cycloalkyl-C 4 -alkyl, R 5 is hydrogen, and R 6 is C 1 . 6 -alkyl; phenyl-C1.4-alkyl, the phenyl group of which is optionally substituted once by halogen; furyl-C 1 .4-alkyl or tetrahydronaphthyl, or R 5 and R 6 , together with the nitrogen to which they are bonded, form a piperazine ring which is optionally substituted by phenyl, characterised in that a compound of the general formula 11, R4 R6 O 3 R2 I O R1 wherein R1, R 2 , R 4 , R 5 and R 6 have the above meanings, is reacted with a compound of the general formula 111, X -SO2-Ra III wherein R 3 has the above meaning and X is a cleavable leaving group.

11. Compounds of the general formula 11, R4 R 5 NH R6 o N 4 OH 3 R2 I wherein R 1 is C1.4-alkyl, R 2 is C1.4-alkyl, R 4 is hydrogen; C 1 .e-alkyl or C 3 . 7 -cycloalkyl-Cl4-alkyl, R 5 is hydrogen, and 39 R6 is C 1 . 6 -alkyl; phenyl-C 1 . 4 -alkyl, the phenyl group of which is optionally substituted once by halogen; furyl-C 1 .4-alkyl or tetrahydronaphthyl, or R 5 and R , together with the nitrogen to which they are bonded, form a piperazine ring which is optionally substituted by phenyl.